Work

Optimal therapeutic positioning of a selective bi-steric inhibitor of MTORC1 in genetically defined cancers

Year: 2020

Type: article

Source: European Journal of Cancer

DOI: 10.1016/s0959-8049(20)31217-x

Authors: J. Jiang, Y.C. Yang, C.J. Schulze, J.W. Evans, Z.C. Wang, B.J. Lee, T.J. Choy, D.F. Reyes, R.P. Zhao, J.Y. Tao, H. Du, T. Ozawa, D.P. Wildes, D.R. Raleigh, Z.P. Wang, S.P. Monga, D.J. Kwiatkowski, W.A. Weiss, J.A. Smith, M. Singh

Institutions: Revolution Medicines (United States), University of Pittsburgh, University of Pittsburgh Medical Center, Brigham and Women's Hospital, University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center

Language: English

Topic: PI3K/AKT/mTOR signaling in cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W3095068463

FWCI: 0.081

Cites:

Cited by: 1

Related to: 10